Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit.
Most likely, the UK is the best environment for putting forward trials that are properly regulated. Initially that tipped a lot of venture capital into the field, but obviously now there is a lot more corporate capital coming in too, which is exactly what we want.
